SLC5A2 and atrial fibrillation: The study demonstrated a statistically significant reduction in the risk of atrial arrhythmias (RR: 0.86; 95% CI: 0.74–0.99; p = 0.04) and atrial fibrillation/flutter (RR: 0.85; 95% CI: 0.74–0.99; p = 0.03) with SGLT2 inhibitor therapy—particularly among individuals with elevated cardiovascular risk and prolonged follow-up.